Literature DB >> 26630260

Advancing treatment options for chronic idiopathic constipation.

Eamonn M M Quigley1, Leila Neshatian1.   

Abstract

INTRODUCTION: Chronic constipation is a global problem affecting all ages and associated with considerable morbidity and significant financial burden for society. Though formerly defined on the basis of a single symptom, infrequent defecation; constipation is now viewed as a syndrome encompassing several complaints such as difficulty with defecation, a sense of incomplete evacuation, hard stools, abdominal discomfort and bloating. AREAS COVERED: The expanded concept of constipation has inevitably led to a significant change in outcomes in clinical trials, as well as in patient expectations from new therapeutic interventions. The past decades have also witnessed a proliferation in therapeutic targets for new agents. Foremost among these have been novel prokinetics, a new category, prosecretory agents and innovative approaches such as inhibitors of bile salt transport. In contrast, relatively few effective therapies exist for the management of those anorectal and pelvic floor problems that result in difficult defecation. EXPERT OPINION: Though constipation is a common and often troublesome disorder, many of those affected can resolve their symptoms with relatively simple measures. For those with more resistant symptoms a number of novel, effective and safe options now exist. Those with defecatory difficulty (anismus, pelvic floor dysfunction) continue to represent a significant management challenge.

Entities:  

Keywords:  Chronic constipation; bile salt transporter inhibitor; biofeedback; botulinum toxin; colectomy; elobixibat; irritable bowel syndrome; linactolide; lubiprostone; plecanatide; prokinetic; prosecretory agent; prucalopride; velusetrag

Mesh:

Year:  2015        PMID: 26630260     DOI: 10.1517/14656566.2016.1127356

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  6 in total

Review 1.  An update on prucalopride in the treatment of chronic constipation.

Authors:  Anam Omer; Eamonn M M Quigley
Journal:  Therap Adv Gastroenterol       Date:  2017-10-16       Impact factor: 4.409

2.  Efficacy of Prucalopride in bowel cleansing before colonoscopy: Results of a pilot study.

Authors:  Vito Domenico Corleto; Giulio Antonelli; Chiara Coluccio; Lucia D'Alba; Emilio di Giulio
Journal:  World J Gastrointest Endosc       Date:  2017-11-16

3.  Clinical Characteristics of Different Primary Constipation Subtypes in a Chinese Population.

Authors:  Ya Jiang; Yurong Tang; Lin Lin
Journal:  J Clin Gastroenterol       Date:  2020-08       Impact factor: 3.174

Review 4.  Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders.

Authors:  Scott A Waldman; Michael Camilleri
Journal:  Gut       Date:  2018-03-21       Impact factor: 23.059

5.  Different doses of prucalopride in treating chronic idiopathic constipation: a meta-analysis and Bayesian analysis.

Authors:  Shizhang Wei; Haotian Li; Tao Yang; Kaili Wang; Yibo Cao; Jianxia Wen; Xiangdong Yang; Tianbao Xiao
Journal:  BMJ Open       Date:  2021-02-15       Impact factor: 2.692

6.  Efficacy and safety of vibrating capsule for functional constipation (VICONS): A randomised, double-blind, placebo-controlled, multicenter trial.

Authors:  Jia-Hui Zhu; Yang-Yang Qian; Jun Pan; Chen He; Yu Lan; Wei-Na Chen; Bang-Mao Wang; Wei Zhao; Jing-Nan Li; Xiao-Qing Li; Bin Lv; Yi-Hong Fan; Xiu-Li Zuo; Zhen Li; Duo-Wu Zou; Zhao-Shen Li; Zhuan Liao
Journal:  EClinicalMedicine       Date:  2022-04-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.